Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed 670G Hybrid Closed-Loop System.

Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Dec;19(12):749-752. doi: 10.1089/dia.2017.0208. Epub 2017 Nov 17.

PMID:
29148821
2.

Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor.

Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Aug;19(8):446-456. doi: 10.1089/dia.2017.0087. Epub 2017 Jul 12.

3.

Evaluation of a Predictive Low-Glucose Management System In-Clinic.

Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR.

Diabetes Technol Ther. 2017 May;19(5):288-292. doi: 10.1089/dia.2016.0319. Epub 2017 Feb 16.

PMID:
28221823
4.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Mar;19(3):155-163. doi: 10.1089/dia.2016.0421. Epub 2017 Jan 30.

5.

New Generation Blood Glucose Monitoring System Exceeds International Accuracy Standards.

Brazg RL, Klaff LJ, Sussman AM.

J Diabetes Sci Technol. 2016 Nov 1;10(6):1414-1415. Print 2016 Nov. No abstract available.

6.

Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.

Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR; ASPIRE In-Home Study Group.

J Diabetes Sci Technol. 2015 May 18;9(5):1016-20. doi: 10.1177/1932296815586014.

7.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

8.

Accuracy evaluation of contour next compared with five blood glucose monitoring systems across a wide range of blood glucose concentrations occurring in a clinical research setting.

Klaff LJ, Brazg R, Hughes K, Tideman AM, Schachner HC, Stenger P, Pardo S, Dunne N, Parkes JL.

Diabetes Technol Ther. 2015 Jan;17(1):8-15. doi: 10.1089/dia.2014.0069.

PMID:
25260047
9.

Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.

Bailey TS, Ahmann A, Brazg R, Christiansen M, Garg S, Watkins E, Welsh JB, Lee SW.

Diabetes Technol Ther. 2014 May;16(5):277-83. doi: 10.1089/dia.2013.0222. Epub 2014 Apr 7.

PMID:
24758729
10.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators.

N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29.

11.

Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study.

Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR.

Diabetes Technol Ther. 2014 Mar;16(3):125-30. doi: 10.1089/dia.2013.0219. Epub 2014 Jan 9.

PMID:
24405492
12.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

13.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

14.

Threshold-based insulin-pump interruption for reduction of hypoglycemia.

Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR; ASPIRE In-Home Study Group.

N Engl J Med. 2013 Jul 18;369(3):224-32. doi: 10.1056/NEJMoa1303576. Epub 2013 Jun 22.

15.

Clinical evaluation of the FreeStyle Precision Pro system.

Brazg R, Hughes K, Martin P, Coard J, Toffaletti J, McDonnell E, Taylor E, Farrell L, Patel M, Ward J, Chen T, Alva S, Ng R.

Clin Chim Acta. 2013 Jun 5;421:243-50. doi: 10.1016/j.cca.2013.03.021. Epub 2013 Mar 26.

16.
17.

Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.

Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR.

Diabetes Technol Ther. 2012 Mar;14(3):205-9. doi: 10.1089/dia.2011.0292. Epub 2012 Feb 8.

PMID:
22316089
18.

The ASPIRE study: design and methods of an in-clinic crossover trial on the efficacy of automatic insulin pump suspension in exercise-induced hypoglycemia.

Brazg RL, Bailey TS, Garg S, Buckingham BA, Slover RH, Klonoff DC, Nguyen X, Shin J, Welsh JB, Lee SW.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1466-71.

19.

Accuracy of the Enlite 6-day glucose sensor with guardian and Veo calibration algorithms.

Keenan DB, Mastrototaro JJ, Zisser H, Cooper KA, Raghavendhar G, Lee SW, Yusi J, Bailey TS, Brazg RL, Shah RV.

Diabetes Technol Ther. 2012 Mar;14(3):225-31. doi: 10.1089/dia.2011.0199. Epub 2011 Dec 6.

PMID:
22145851
20.

Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

O'Leary DH, Reuwer AQ, Nissen SE, Després JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators.

Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24.

PMID:
21610270

Supplemental Content

Loading ...
Support Center